PharmaFocus: Biomarkers in Alzheimer's Disease - PowerPoint PPT Presentation

View by Category
About This Presentation

PharmaFocus: Biomarkers in Alzheimer's Disease

Description: announces a new report on "PharmaFocus: Biomarkers in Alzheimer's Disease", Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. – PowerPoint PPT presentation

Number of Views:61


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: PharmaFocus: Biomarkers in Alzheimer's Disease

PharmaFocus Biomarkers in Alzheimer's Disease
One-Stop Shop for Business Information
Alzheimers disease (AD) is a progressive
neurodegenerative disease that is characterized
by memory loss, cognitive impairment, and
functional decline. The disease has emerged as a
major global health priority especially because
of its rapidly accelerating prevalence worldwide.
In order to tackle the AD scourge , there is an
urgent need for tools that will allow for the
early and accurate diagnosis of AD, as well as
the identification of populations at risk. A
biomarker is an indicator of biological processes
that can be objectively measured and evaluated,
and well-validated biomarkers are required to
satisfy these needs in AD.The search for
biomarkers that are reflective of the disease
process in AD has been and continues to be an
active area of research, but has been hampered by
a lack of clear understanding of the pathological
mechanisms that underlie the disease.
  • Nonetheless, several biomarkers have been
    developed to date that indicate the presence of
    AD pathology and AD-associated neuronal injury in
    vivo. Such biomarkers have the potential for
    clinical use in etiological determination,
    predictive prognosis, monitoring disease
    progression, and in clinical trials of potential
    disease-modifying therapies for AD.
  • Scope
  • Overview of Alzheimer's disease, including
    disease etiology and pathophysiology and how
    these inform biomarker targets. - Overview of AD
    biomarkers, the major classes of biomarkers an
    the different potential roles of biomarkers in
    clinical use and drug development.
  • - Key topics covered include amyloid biomarkers,
    tau biomarkers, and other molecular biomarkers
    for AD in development with product profiles for
    marketed as well as promising pipeline assays.

  • Also discussed are functional and structural
    imaging biomarkers for AD.
  • Analysis of the unmet needs, and opportunities
    within the AD biomarker arena, as well as drivers
    and barriers impacting the AD biomarker market.-
    Insightful review of the regulatory
    considerations impacting biomarker development,
    market access and use in clinical drug
  • Key Benefits
  • Develop and design your in-licensing and
    out-licensing strategies through a review of
    pipeline products and technologies, and by
    identifying the companies with the most robust
  • Develop business strategies by understanding the
    factors shaping and driving AD biomarker
    development and market adoption.

Table Of Content
  1. Table of Contents
  2. Introduction
  3. Alzheimers Disease Overview
  4. AD Biomarkers Overview
  5. Unmet Needs Assessment
  6. AD Biomarkers Market Drivers and Barriers
  7. Amyloid Beta Biomarkers
  8. Tau-Related Biomarkers
  9. Beyond Amyloid and Tau Other Molecular AD
    Biomarkers in Development
  10. Functional Brain Imaging Biomarkers
  11. Structural Brain Imaging Biomarkers

  • To know more
  • PharmaFocus Biomarkers in Alzheimer's Disease

Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 Email id